TCF12
Basic information
Region (hg38): 15:56918623-57299281
Links
Phenotypes
GenCC
Source:
- TCF12-related craniosynostosis (Strong), mode of inheritance: AD
- Kallmann syndrome (Strong), mode of inheritance: AR
- Kallmann syndrome (Strong), mode of inheritance: AD
- TCF12-related craniosynostosis (Strong), mode of inheritance: AD
- isolated plagiocephaly (Supportive), mode of inheritance: AD
- isolated brachycephaly (Supportive), mode of inheritance: AD
- hypogonadotropic hypogonadism 26 with or without anosmia (Strong), mode of inheritance: AD
- TCF12-related craniosynostosis (Strong), mode of inheritance: AD
- TCF12-related craniosynostosis (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hypogonadotropic hypogonadism 26 with or without anosmia | AD | Endocrine | In Hypogonadotropic hypogonadism, surveillance in adolescence related to sexual maturation is indicated, as is monitoring of bone mineral density in order to allow early detection and treatment of disease | Craniofacial; Endocrine; Musculoskeletal; Neurologic | 23354436 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (35 variants)
- TCF12-related craniosynostosis (14 variants)
- Inborn genetic diseases (3 variants)
- HYPOGONADOTROPIC HYPOGONADISM 26 WITH ANOSMIA (1 variants)
- Craniosynostosis syndrome (1 variants)
- TCF12-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TCF12 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 15 | 22 | ||||
missense | 93 | 10 | 108 | |||
nonsense | 16 | 23 | ||||
start loss | 0 | |||||
frameshift | 26 | 11 | 42 | |||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 11 | |||||
splice region | 2 | 3 | 6 | 3 | 1 | 15 |
non coding | 44 | 41 | 88 | |||
Total | 44 | 29 | 106 | 69 | 47 |
Highest pathogenic variant AF is 0.00000658
Variants in TCF12
This is a list of pathogenic ClinVar variants found in the TCF12 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-56919557-G-A | Likely benign (Apr 18, 2021) | |||
15-56919764-G-A | Likely benign (May 20, 2019) | |||
15-56919800-C-G | Likely benign (Jan 02, 2019) | |||
15-56919924-A-T | Uncertain significance (Jan 26, 2022) | |||
15-56919932-C-T | Uncertain significance (Dec 19, 2023) | |||
15-56919932-C-CG | Hypogonadism with anosmia | Uncertain significance (Feb 02, 2022) | ||
15-56919935-A-G | Inborn genetic diseases | Uncertain significance (Jun 18, 2024) | ||
15-56919936-T-C | Uncertain significance (Feb 07, 2022) | |||
15-56919970-C-T | Likely benign (May 21, 2018) | |||
15-56919972-TA-T | Likely pathogenic (Nov 06, 2018) | |||
15-56920007-G-C | Benign (Jul 18, 2023) | |||
15-56920030-TTTTG-T | Likely benign (May 23, 2021) | |||
15-56920275-G-A | Likely benign (Jan 18, 2020) | |||
15-56920821-A-G | Benign (Oct 16, 2018) | |||
15-56920981-T-C | Likely benign (Jan 02, 2019) | |||
15-56921008-A-G | not specified | Benign (Jan 16, 2024) | ||
15-56921030-T-A | Uncertain significance (Aug 27, 2023) | |||
15-56921057-C-G | Inborn genetic diseases | Uncertain significance (Dec 30, 2023) | ||
15-56921062-C-T | Uncertain significance (Oct 09, 2023) | |||
15-56921080-A-G | Inborn genetic diseases | Uncertain significance (Mar 02, 2023) | ||
15-56921085-A-G | not specified | Benign (Jan 15, 2024) | ||
15-56921093-G-A | Uncertain significance (Feb 27, 2023) | |||
15-56921373-G-A | Benign (Nov 08, 2018) | |||
15-57063764-G-C | Inborn genetic diseases | Uncertain significance (May 01, 2024) | ||
15-57063806-TC-T | TCF12-related craniosynostosis | Pathogenic (May 12, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TCF12 | protein_coding | protein_coding | ENST00000438423 | 19 | 380659 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.676 | 0.324 | 125728 | 0 | 20 | 125748 | 0.0000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.890 | 338 | 387 | 0.873 | 0.0000195 | 4593 |
Missense in Polyphen | 107 | 179.87 | 0.59487 | 2061 | ||
Synonymous | -1.40 | 158 | 137 | 1.15 | 0.00000695 | 1385 |
Loss of Function | 4.58 | 8 | 38.8 | 0.206 | 0.00000199 | 474 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000272 | 0.000271 |
Ashkenazi Jewish | 0.0000994 | 0.0000992 |
East Asian | 0.000164 | 0.000163 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000794 | 0.0000791 |
Middle Eastern | 0.000164 | 0.000163 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3').;
- Disease
- DISEASE: Craniosynostosis 3 (CRS3) [MIM:615314]: A primary abnormality of skull growth involving premature fusion of one or more cranial sutures. The growth velocity of the skull often cannot match that of the developing brain resulting in an abnormal head shape and, in some cases, increased intracranial pressure, which must be treated promptly to avoid permanent neurodevelopmental disability. {ECO:0000269|PubMed:23354436, ECO:0000269|PubMed:25271085}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Developmental Biology;Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription;CDO in myogenesis;Myogenesis;RUNX1 regulates transcription of genes involved in differentiation of HSCs;Transcriptional regulation by RUNX1
(Consensus)
Recessive Scores
- pRec
- 0.190
Intolerance Scores
- loftool
- 0.622
- rvis_EVS
- -0.71
- rvis_percentile_EVS
- 14.67
Haploinsufficiency Scores
- pHI
- 0.741
- hipred
- Y
- hipred_score
- 0.749
- ghis
- 0.643
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tcf12
- Phenotype
- immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype;
Gene ontology
- Biological process
- regulation of transcription by RNA polymerase II;immune response;muscle organ development;positive regulation of neuron differentiation;positive regulation of transcription by RNA polymerase II;regulation of hematopoietic stem cell differentiation
- Cellular component
- nuclear chromatin;nucleus;nucleoplasm;transcription factor complex;cytoplasm;nuclear speck;intracellular membrane-bounded organelle;RNA polymerase II transcription factor complex
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;transcription factor binding;enhancer binding;cAMP response element binding;protein homodimerization activity;bHLH transcription factor binding;transcription regulatory region DNA binding;SMAD binding;protein heterodimerization activity;E-box binding;HMG box domain binding